Arcalyst Approval History

• FDA approved: Yes (First approved February 27th, 2008)
• Brand name: Arcalyst
• Generic name: rilonacept
• Previous name: Interleukin-1 Trap
• Company: Regeneron Pharmaceuticals, Inc.
• Treatment for: Cryopyrin-Associated Periodic Syndromes

Arcalyst (rilonacept) is an interleukin-1 inhibitor for the long-term treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).

FDA Approval History for Arcalyst

Date	Article
Feb 28, 2008	FDA Approves Arcalyst - New Orphan Drug for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Nov  2, 2007	PDUFA Date for Rilonacept (IL-1 Trap) Extended Three Months by FDA
Aug  8, 2007	Rilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS
Jun  8, 2007	Regeneron Submits Biologics License Application to U.S. FDA for IL-1 Trap (Rilonacept) for Treatment of CAPS

See also...

Arcalyst (rilonacept) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.